View Item 

Show simple item record

Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide populationâ based, propensityâ scoreâ matched cohort study
dc.contributor.authorKuo, Shihchen
dc.contributor.authorYang, Chun‐ting
dc.contributor.authorWu, Jin‐shang
dc.contributor.authorOu, Huang‐tz
dc.date.accessioned2019-02-12T20:23:12Z
dc.date.available2020-04-01T15:06:24Zen
dc.date.issued2019-02
dc.identifier.citationKuo, Shihchen; Yang, Chun‐ting ; Wu, Jin‐shang ; Ou, Huang‐tz (2019). "Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide populationâ based, propensityâ scoreâ matched cohort study." Diabetes, Obesity and Metabolism 21(2): 312-320.
dc.identifier.issn1462-8902
dc.identifier.issn1463-1326
dc.identifier.urihttps://hdl.handle.net/2027.42/147778
dc.publisherBlackwell Publishing Ltd
dc.publisherWiley Periodicals, Inc.
dc.subject.otherinsulin therapy
dc.subject.othertype 2 diabetes
dc.subject.otherhypoglycaemia
dc.subject.othercohort study
dc.subject.othercardiovascular disease
dc.subject.otherantidiabetic drug
dc.titleEffects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide populationâ based, propensityâ scoreâ matched cohort study
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147778/1/dom13525_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147778/2/dom13525.pdf
dc.identifier.doi10.1111/dom.13525
dc.identifier.sourceDiabetes, Obesity and Metabolism
dc.identifier.citedreferenceDehejia RH, Wahba S. Propensity scoreâ matching methods for nonexperimental causal studies. Rev Econ Stat. 2002; 84 ( 1 ): 151 â 161.
dc.identifier.citedreferenceChang CH, Lee YC, Tsai CT, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis. 2014; 232 ( 1 ): 224 â 230.
dc.identifier.citedreferenceLin YS, Chen TH, Chi CC, et al. Different implications of heart failure, ischemic stroke, and mortality between nonvalvular atrial fibrillation and atrial flutter: a view from a national cohort study. J Am Heart Assoc. 2017; 6 ( 7 ):e006406.
dc.identifier.citedreferenceWu CS, Lai MS, Gau SS, Wang SC, Tsai HJ. Concordance between patient selfâ reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. PLoS One. 2014; 9 ( 12 ):e112257.
dc.identifier.citedreferenceSung SF, Hsieh CY, Lin HJ, Chen YW, Yang YH, Li CY. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol. 2016; 215: 277 â 282.
dc.identifier.citedreferenceGinde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICDâ 9â CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008; 8: 4.
dc.identifier.citedreferenceChang HY, Weiner J, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012; 18 ( 11 ): 721 â 726.
dc.identifier.citedreferenceCheng Câ L, Chien Hâ C, Lee Câ H, Lin Sâ J, Yang Yâ HK. Validity of inâ hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol. 2015; 201: 96 â 101.
dc.identifier.citedreferenceOu HT, Chang KC, Li CY, Wu JS. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other secondâ and thirdâ line antidiabetic drugs in patients with type 2 diabetes. Br J Clin Pharmacol. 2017; 83 ( 7 ): 1556 â 1570.
dc.identifier.citedreferenceParsons LS. Reducing bias in a propensity score matchedâ pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc.; 2001: 214 â 226.
dc.identifier.citedreferenceMeduru P, Helmer D, Rajan M, Tseng Câ L, Pogach L, Sambamoorthi U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007; 22 ( 3 ): 408 â 418.
dc.identifier.citedreferenceCohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Publishers; 1988.
dc.identifier.citedreferenceAustin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009; 38 ( 6 ): 1228 â 1234.
dc.identifier.citedreferenceYang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS. SAS Global Forum 2012: Statistics and Data Analysis; Paper 335â 2012.
dc.identifier.citedreferenceLin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingaleâ based residuals. Biometrika. 1993; 80 ( 3 ): 557 â 572.
dc.identifier.citedreferenceLee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018; 41 ( 1 ): 104 â 111.
dc.identifier.citedreferenceGoto A, Goto M, Terauchi Y, Yamaguchi N, Noda M. Association between severe hypoglycemia and cardiovascular disease risk in Japanese patients with type 2 diabetes. J Am Heart Assoc. 2016; 5 ( 3 ):e002875.
dc.identifier.citedreferenceStandl E, Stevens SR, Armstrong PW, et al. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an atâ risk type 2 diabetes frail patient phenotype. Diabetes Care. 2018; 41 ( 3 ): 596 â 603.
dc.identifier.citedreferenceMellbin LG, Rydén L, Riddle MC, et al. ORIGIN Trial Investigators. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013; 34 ( 40 ): 3137 â 3144.
dc.identifier.citedreferenceZinman B, Marso SP, Christiansen E, et al. Hypoglycemia, cardiovascular outcomes, and death: The LEADER Experience. Diabetes Care. 2018; 41 ( 8 ): 1783 â 1791.
dc.identifier.citedreferenceFreemantle N, Danchin N, Calviâ Gries F, Vincent M, Home P. Relationship of glycaemic control and hypoglycaemic episodes to 4â year cardiovascular outcomes in people with type 2 diabetes starting insulin. Diabetes Obes Metab. 2016; 18 ( 2 ): 152 â 158.
dc.identifier.citedreferenceMonami M, Marchionni N, Mannucci E. Longâ acting insulin analogues versus NPH human insulin in type 2 diabetes: a metaâ analysis. Diabetes Res Clin Pract. 2008; 81 ( 2 ): 184 â 189.
dc.identifier.citedreferenceHorvath K, Jeitler K, Berghold A, et al. Longâ acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;( 2 ):CD005613.
dc.identifier.citedreferenceLingvay I, Kaloyanova PF, Adamsâ Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes. J Invest Med. 2007; 55 ( 2 ): 62 â 68.
dc.identifier.citedreferenceHarrison LB, Adamsâ Huet B, Raskin P, Lingvay I. βâ cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012; 35 ( 7 ): 1406 â 1412.
dc.identifier.citedreferenceWeng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on βâ cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallelâ group trial. Lancet. 2008; 371 ( 9626 ): 1753 â 1760.
dc.identifier.citedreferenceKhunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes. Diabetes Care. 2013; 36 ( 11 ): 3411 â 3417.
dc.identifier.citedreferenceLin SD, Tsai ST, Tu ST, et al. Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulinâ requiring type 2 diabetes. Prim Care Diabetes. 2015; 9 ( 2 ): 135 â 141.
dc.identifier.citedreferencePeyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010; 4: S11 â S18.
dc.identifier.citedreferenceKarter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010; 33 ( 4 ): 733 â 735.
dc.identifier.citedreferenceChen KW, Tseng Hâ M. The barriers to initiating insulin therapy among people with type 2 diabetes in Taiwan â A qualitative study. J Diabetes Metab. 2012; 3: 194.
dc.identifier.citedreferenceAmerican Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017; 40 ( suppl 1 ): S64 â S74.
dc.identifier.citedreferenceHolman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10â Year followâ up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577 â 1589.
dc.identifier.citedreferenceOrigin Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 2012 ( 367 ): 319 â 328.
dc.identifier.citedreferenceChaitman BR, Hardison RM, Adler D, et al. The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease. Circulation. 2009; 120 ( 25 ): 2529 â 2540.
dc.identifier.citedreferenceMellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L, DIGAMI 2 Investigators. Prognostic implications of glucoseâ lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended followâ up of the diabetes mellitus insulinâ glucose infusion in acute myocardial infarction (DIGAMI) 2 study. Diabetologia. 2011; 54 ( 6 ): 1308 â 1317.
dc.identifier.citedreferenceAnyanwagu U, Mamza J, Donnelly R, Idris I. Comparison of cardiovascular and metabolic outcomes in people with type 2 diabetes on insulin versus nonâ insulin glucoseâ lowering therapies (GLTs): a systematic review and metaâ analysis of clinical trials. Diabetes Res Clin Pract. 2016; 121: 69 â 85.
dc.identifier.citedreferencePalmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucoseâ lowering drugs in patients with type 2 diabetes: a metaâ analysis. JAMA. 2016; 316 ( 3 ): 313 â 324.
dc.identifier.citedreferenceMonami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a metaâ analysis of randomized clinical trials. Diabetes Obes Metab. 2013; 15 ( 10 ): 938 â 953.
dc.identifier.citedreferenceCurrie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetesâ related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013; 98 ( 2 ): 668 â 677.
dc.identifier.citedreferenceRoumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and allâ cause mortality among patients with diabetes. JAMA. 2014; 311 ( 22 ): 2288 â 2296.
dc.identifier.citedreferenceNystrom T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Second line initiation of insulin compared with DPPâ 4 inhibitors after metformin monotherapy is associated with increased risk of allâ cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract. 2017; 123: 199 â 208.
dc.identifier.citedreferenceEkstrom N, Svensson AM, Miftaraj M, et al. Cardiovascular safety of glucoseâ lowering agents as addâ on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Diabetes Obes Metab. 2016; 18 ( 10 ): 990 â 998.
dc.identifier.citedreferenceGamble JM, Thomas JM, Twells LK, Midodzi WK, Majumdar SR. Comparative effectiveness of incretinâ based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine (Baltimore). 2016; 95 ( 26 ):e3995.
dc.identifier.citedreferenceAnyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I. Cardiovascular events and allâ cause mortality with insulin versus glucagonâ like peptideâ 1 analogue in type 2 diabetes. Heart. 2016; 102 ( 19 ): 1581 â 1587.
dc.identifier.citedreferenceJil M, Rajnikant M, Richard D, Iskandar I. The effects of dualâ therapy intensification with insulin or dipeptidylpeptidaseâ 4 inhibitor on cardiovascular events and allâ cause mortality in patients with type 2 diabetes: a retrospective cohort study. Diab Vasc Dis Res. 2017; 14 ( 4 ): 295 â 303.
dc.identifier.citedreferenceHippisleyâ Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016; 354: i3477.
dc.identifier.citedreferenceGoto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and metaâ analysis with bias analysis. BMJ. 2013; 347: f4533.
dc.identifier.citedreferenceCha SA, Yun JS, Lim TS, et al. Severe hypoglycemia and cardiovascular or allâ cause mortality in patients with type 2 diabetes. Diabetes Metab J. 2016; 40 ( 3 ): 202 â 210.
dc.identifier.citedreferenceZoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363: 1410 â 1418.
dc.identifier.citedreferenceCheng Tâ M. Taiwan’s new national health insurance program: genesis and experience so far. Health Aff. 2003; 22 ( 3 ): 61 â 76.
dc.identifier.citedreferenceLin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005; 104 ( 3 ): 157 â 163.
dc.identifier.citedreferenceCheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011; 20: 236 â 242.
dc.identifier.citedreferenceCheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YHK. Validation of acute myocardial infarction cases in the National Health Insurance Research database in Taiwan. J Epidemiol. 2014; 24: 500 â 507.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
dom13525_am.pdf
Size:
303.9KB
Format:
PDF
View/Open
Name:
dom13525.pdf
Size:
603.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.